Your browser doesn't support javascript.
loading
Letter to the Editor: Update to: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Rubel, C; Chen, T; Dent, G.
Affiliation
  • Rubel C; Gersham Dent, PhD, Biogen Inc, Cambridge, MA, USA Tel: 617-679-2081; email: gersham.dent@biogen.com.
J Prev Alzheimers Dis ; 11(4): 1178-1179, 2024.
Article in En | MEDLINE | ID: mdl-39044530
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Randomized Controlled Trials as Topic / Alzheimer Disease / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: J Prev Alzheimers Dis Year: 2024 Document type: Article Country of publication: Switzerland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Randomized Controlled Trials as Topic / Alzheimer Disease / Antibodies, Monoclonal, Humanized Limits: Humans Language: En Journal: J Prev Alzheimers Dis Year: 2024 Document type: Article Country of publication: Switzerland